<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00589381</url>
  </required_header>
  <id_info>
    <org_study_id>080030</org_study_id>
    <secondary_id>08-C-0030</secondary_id>
    <secondary_id>NCI-P07187</secondary_id>
    <secondary_id>CDR0000580777</secondary_id>
    <nct_id>NCT00589381</nct_id>
  </id_info>
  <brief_title>Fenretinide Lym-X-Sorb™ in Treating Patients With Recurrent or Resistant Solid Tumors or Lymphoma</brief_title>
  <official_title>Phase I Trial of Fenretinide (4-HPR, NSC 374551) Lym-X-Sorb™ (LXS) Oral Powder (4-HPR/LXS Oral Powder) (4-HPR) in Adults With Solid Tumors and Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institutes of Health Clinical Center (CC)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as fenretinide Lym-X-Sorb™ , work in different&#xD;
      ways to stop the growth of cancer cells, either by killing the cells or by stopping them from&#xD;
      dividing.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of fenretinide&#xD;
      Lym-X-Sorb™ in treating patients with recurrent or resistant solid tumors or lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To determine the maximum tolerated dose of fenretinide Lym-X-Sorb™ oral powder&#xD;
           (4-HPR/LXS oral powder) in patients with recurrent and/or resistant solid tumors or&#xD;
           lymphomas.&#xD;
&#xD;
        -  To define the toxicities of 4-HPR/LXS oral powder in these patients.&#xD;
&#xD;
        -  To determine the plasma pharmacokinetics of 4-HPR/LXS oral powder in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To determine the level of fenretinide delivered as 4-HPR/LXS oral powder in normal&#xD;
           peripheral blood mononuclear cells.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive oral fenretinide Lym-X-Sorb™ oral powder (4-HPR/LXS oral powder) (mixed in&#xD;
      food carriers) three times daily on days 1-7. Treatment repeats every 21 days for 6 courses&#xD;
      in the absence of disease progression or unacceptable toxicity. Patients achieving stable&#xD;
      disease response or better may receive additional courses of treatment at the discretion of&#xD;
      the treating physician and principal investigator.&#xD;
&#xD;
      Blood samples are collected periodically for pharmacokinetic and pharmacodynamic studies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of 4-HPR/LXS oral powder</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Level of fenretinide in normal peripheral blood mononuclear cells</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Lymphoma</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fenretinide lipid matrix</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed (by the NIH pathology department) diagnosis of 1 of the&#xD;
             following:&#xD;
&#xD;
               -  Solid tumor malignancy that is metastatic or unresectable&#xD;
&#xD;
               -  Lymphoma for which standard treatment or curative measures do not exist, or are&#xD;
                  associated with minimal patient survival benefit&#xD;
&#xD;
          -  Recurrent and/or resistant disease&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
               -  Patients whose brain metastatic disease status has remained stable for ≥ 3 months&#xD;
                  after treatment may be eligible at the discretion of the principal investigator&#xD;
                  (without steroids or anti-seizure medications)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100%&#xD;
&#xD;
          -  Life expectancy ≥ 3 months&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/µL&#xD;
&#xD;
          -  Platelets ≥ 100,000/µL (CTCAE v.3 grade 1 thrombocytopenia allowed if explained by&#xD;
             involvement of the bone marrow by lymphoma)&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 times normal institutional limits (2.5 mg/dL for patients with&#xD;
             Gilbert's syndrome)&#xD;
&#xD;
          -  AST (SGOT)/ALT (SGPT) ≤ 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Creatinine &lt; 1.5 times ULN OR creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use two methods of birth control, including at least one highly&#xD;
             effective method (e.g., intrauterine device [IUD], hormonal birth control&#xD;
             pills/injections/implants, tubal ligation or partner's vasectomy), and one additional&#xD;
             effective method (e.g., latex condoms, diaphragm, or cervical cap), prior to, during,&#xD;
             and for 2 months after completion of study treatment&#xD;
&#xD;
               -  Men must use a latex condom every time they have sexual intercourse during&#xD;
                  therapy and for 2 months after discontinuing fenretinide, even if they have had a&#xD;
                  successful vasectomy&#xD;
&#xD;
          -  No clinically significant illnesses which could compromise participation in the study,&#xD;
             including, but not limited to, any of the following:&#xD;
&#xD;
               -  Active or uncontrolled infection&#xD;
&#xD;
               -  Immune deficiencies or confirmed diagnosis of HIV infection&#xD;
&#xD;
               -  Uncontrolled diabetes&#xD;
&#xD;
               -  Uncontrolled hypertension&#xD;
&#xD;
               -  Symptomatic congestive heart failure&#xD;
&#xD;
               -  Unstable angina pectoris&#xD;
&#xD;
               -  Myocardial infarction within the past 6 months&#xD;
&#xD;
               -  Uncontrolled cardiac arrhythmia&#xD;
&#xD;
               -  Psychiatric illness/social situations that would limit compliance with study&#xD;
                  requirements&#xD;
&#xD;
          -  No known wheat gluten allergy or allergy or sensitivity to the study drug&#xD;
&#xD;
          -  No history of pancreatitis as evidenced by elevated amylase or lipase ≥ grade 2 and&#xD;
             accompanied by symptoms of pancreatitis (e.g., abdominal pain)&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Recovered from adverse events and/or toxicity due to prior chemotherapy or biologic&#xD;
             therapy&#xD;
&#xD;
          -  No chemotherapy or biologic therapy within 4 weeks prior to entering the study (6&#xD;
             weeks for nitrosoureas, mitomycin C, or UCN-01)&#xD;
&#xD;
          -  At least 1 month since any prior radiotherapy or major surgery&#xD;
&#xD;
          -  At least 2 weeks since any prior administration of study drug in an exploratory&#xD;
             IND/phase 0 study&#xD;
&#xD;
          -  Patients receiving bisphosphonates for any cancer or undergoing androgen deprivation&#xD;
             therapy for prostate cancer are eligible for this therapy&#xD;
&#xD;
          -  No concurrent sulfonamides&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No other concurrent cancer chemotherapy, or immunomodulating agents (including&#xD;
             systemic corticosteroids)&#xD;
&#xD;
          -  Patients must not take any drugs suspected of causing pseudo tumor cerebri, including&#xD;
             any of the following:&#xD;
&#xD;
               -  Tetracycline&#xD;
&#xD;
               -  Nalidixic acid&#xD;
&#xD;
               -  Nitrofurantoin&#xD;
&#xD;
               -  Phenytoin&#xD;
&#xD;
               -  Sulfonamides&#xD;
&#xD;
               -  Lithium&#xD;
&#xD;
               -  Amiodarone&#xD;
&#xD;
               -  Vitamin A (except as part of routine total parenteral nutrition vitamin&#xD;
                  supplements or in a single daily standard dose oral multivitamin supplement)&#xD;
&#xD;
          -  No concurrent herbal supplements or other alternative therapy medications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shivaani Kummar, MD</last_name>
    <role>Study Chair</role>
    <affiliation>NCI - Medical Oncology Branch</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Childrens Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027-0700</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USC/Norris Comprehensive Cancer Center and Hospital</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90089</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michael and Dianne Bienes Comprehensive Cancer Center at Holy Cross Hospital</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Kummar S, Gutierrez ME, Maurer BJ, Reynolds CP, Kang M, Singh H, Crandon S, Murgo AJ, Doroshow JH. Phase I trial of fenretinide lym-x-sorb oral powder in adults with solid tumors and lymphomas. Anticancer Res. 2011 Mar;31(3):961-6.</citation>
    <PMID>21498721</PMID>
  </results_reference>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>December 20, 2007</study_first_submitted>
  <study_first_submitted_qc>December 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2008</study_first_posted>
  <last_update_submitted>March 7, 2012</last_update_submitted>
  <last_update_submitted_qc>March 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 8, 2012</last_update_posted>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
  <keyword>anaplastic large cell lymphoma</keyword>
  <keyword>angioimmunoblastic T-cell lymphoma</keyword>
  <keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
  <keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
  <keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
  <keyword>Waldenström macroglobulinemia</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fenretinide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

